Literature DB >> 23891655

Sofosbuvir-based interferon-free therapy for patients with HCV infection.

Tarik Asselah1.   

Abstract

Entities:  

Keywords:  Chronic hepatitis C; DAA; Direct-acting antivirals; Gilead; IFN; NS5A inhibitors; PegIFN; RBV; RVR; Resistance; SVR; Safety; Sustained virological response; direct-acting antivirals; eRVR; extended rapid virological response; interferon; pegylated interferon; rapid virologic response; ribavirin; sustained virological response

Mesh：

Substances：

Year:  2013        PMID： 23891655     DOI： 10.1016/j.jhep.2013.07.023

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  4 in total

Review 1.  Enhancing our understanding of current therapies for hepatitis C virus (HCV).

Authors:  Neliswa A Gogela; Ming V Lin; Jessica L Wisocky; Raymond T Chung
Journal:  Curr HIV/AIDS Rep       Date:  2015-03       Impact factor: 5.071

Review 2.  Daclatasvir: potential role in hepatitis C.

Authors:  Choongho Lee
Journal:  Drug Des Devel Ther       Date:  2013-10-16       Impact factor: 4.162

3.  The versatile nature of the 6-aminoquinolone scaffold: identification of submicromolar hepatitis C virus NS5B inhibitors.

Authors:  Giuseppe Manfroni; Rolando Cannalire; Maria Letizia Barreca; Neerja Kaushik-Basu; Pieter Leyssen; Johan Winquist; Nunzio Iraci; Dinesh Manvar; Jan Paeshuyse; Rupa Guhamazumder; Amartya Basu; Stefano Sabatini; Oriana Tabarrini; U Helena Danielson; Johan Neyts; Violetta Cecchetti
Journal:  J Med Chem       Date:  2013-11-06       Impact factor: 7.446

Review 4.  Sofosbuvir: first global approval.

Authors:  Gillian M Keating; Asha Vaidya
Journal:  Drugs       Date:  2014-02       Impact factor: 11.431
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.